Tifacogin and Mortality in Severe Community-Acquired Pneumonia

In a randomized, multicenter, placebo-controlled study, 28-day mortality was no better with tifacogin — a recombinant tissue factor pathway inhibitor — than with placebo.

Endothelial cell injury during sepsis leads to activation of the coagulation process through tissue factor (TF), resulting in capillary thrombosis and eventual organ failure and death. Tissue factor pathway inhibitor (TFPI) inhibits the procoagulant activity of TF. A recombinant TFPI, tifacogin, did not improve survival in a phase III study among individuals with sepsis, but subgroup analysis (Crit Care 2009; 13:R36) suggested benefit in patients with severe community-acquired pneumonia (sCAP).

Now, researchers have conducted a manufacturer-sponsored, phase III, double-blind trial (CAPTIVATE) to examine the efficacy and safety of tifacogin in patients with sCAP. The study was performed between May 2004 and July 2008 at 188 medical centers wo…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Tifacogin and Mortality in Severe Community-Acquired Pneumonia

Topics

Reviewing Author